ANRO (Alto Neuroscience) Pre-Tax Income : $-61.43 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Alto Neuroscience's pretax income for the three months ended in Dec. 2024 was $-15.20 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-61.43 Mil. Alto Neuroscience's pretax margin was %.

During the past 4 years, Alto Neuroscience's highest Pretax Margin was -4374.76%. The lowest was -4374.76%. And the median was -4374.76%.

Alto Neuroscience Pre-Tax Income Historical Data

The historical data trend for Alto Neuroscience's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Pre-Tax Income Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

-9.19

-27.71

-36.31

-61.43

Alto Neuroscience Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial					-11.22	-13.42	-16.03	-16.78	-15.20

Competitive Comparison of Alto Neuroscience's Pre-Tax Income

For the Biotechnology subindustry, Alto Neuroscience's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Alto Neuroscience Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Alto Neuroscience's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-68.61	+	-0.297	+	-1.375	+	8.851	+	0
	=	-61.43

Alto Neuroscience's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-16.997	+	-0.006	+	-0.333	+	2.135	+	-1.7763568394003E-15
	=	-15.20

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-61.43 Mil.

Alto Neuroscience (NYSE:ANRO) Pre-Tax Income Explanation

Alto Neuroscience's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-15.201	/	0
	=	%

During the past 4 years, Alto Neuroscience's highest Pretax Margin was -4374.76%. The lowest was -4374.76%. And the median was -4374.76%.

Alto Neuroscience Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

369 South San Antonio Road, Los Altos, CA, USA, 94022

Website

https://www.altoneuroscience.com

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.